Evaluation of Plasma Renin Concentrations in Cardiac Surgery
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to learn more about how renin (a blood test) is affected by cardiopulmonary bypass, the heart-lung machine used during open heart surgery. Renin is a protein that may be elevated in response to low blood pressure or situations where organs do not receive sufficient oxygen. Renin may potentially be used as an indicator for specific treatments aimed to increase the blood pressure. This study will evaluate blood samples for renin concentration throughout the course of open heart surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult persons 18 years of age or greater.
Scheduled for an elective cardiac surgical procedure involving the use of cardiopulmonary bypass.
Disqualifiers
Surgery involving heart or lung transplantation or implant of a durable left ventricular assist device.
Emergency cardiac surgery.
Established diagnosis of any congenital heart disease.
End-stage kidney disease receiving kidney replacement therapy before surgery.
Trial population
Adult persons 18 years of age or greater (female and male).
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Plasma renin concentrations
Time frame
Up to 24 hours after surgerySecondary outcomes
1
Vasoplegia
Requirement of any vasopressor to maintain a mean arterial pressure of 65 mmHg or greater despite a cardiac index of at least 2.2 L/min/m2 with or without the need for pharmacologic inotropy
Time frame
First 24 hours postoperative2
Acute kidney injury
Assessed by the Kidney Disease Improving Global Outcomes (KDIGO) staging criteria
Time frame
7 days3
Organ dysfunction
The presence of any organ support therapy including vasopressors, renal replacement therapy, and mechanical ventilation
Time frame
28 days4
Mortality
Time frame
28 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov